La Jolla Institute for Allergy and Immunology

Sanford Burnham Prebys Medical Discovery Institute

La Jolla Institute of Allergy & Immunology

University of California

Stephanie M Stanford

Nunzio Bottini

Anthony B Pinkerton

Robert J Ardecky

Jiwen Zou

Michael P Hedrick

Santhi Reddy Ganji

Thomas D Y Chung

Gary S Firestein

Cristiano Sacchetti

Santhi R Ganji

Thomas Chung

Methods of treating fibrotic diseases and disorders including Systemic sclerosis (SSc) are provided. Methods include, for example, administering to a subject an effective amount of an antagonist/inhibitor of PTP4A1 protein expression or activity to treat a fibrotic disease or disorder such as SSc, or an associated pathology such as organ or skin fibrosis.

PTP4A1 as a therapeutic target for fibrotic diseases and disorders including systemic sclerosis

Herein are provided, inter, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A). 

Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof

Herein are provided, inter alia, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A). 

Presented is a method for treating inflammation and autoimmune diseases through the use of a phosphatase rheumatoid arthritis (PT-PRA) antagonist.

Modulation of PTPRA to treat arthritis

There are provided, inter alia, methods and compositions to treat autoimmune disease including invasiveness of fibroblast-like synoviocytes in rheumatoid arthritis.

Autoimmune disease treatments

Growing community of inventors

La Jolla, CA, United States of America

Stephanie M Stanford